Endotoxin-neutralizing activity of polymyxin B in blood after IV administration in horses

American Journal of Veterinary Research

Volumn 67, Issue 4, 2006, Pages 642-647

  Morresey, Peter R ^a,b   MacKay, Robert J ^a  

^a University of Florida College of Veterinary Medicine   (United States)

^b ROOD AND RIDDLE EQUINE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CREATININE; ENDOTOXIN; GAMMA GLUTAMYLTRANSFERASE; LIPOPOLYSACCHARIDE; NITRITE; POLYMYXIN B;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG SAFETY; ENDOTOXEMIA; FEMALE; HORSE; MALE; MULTIPLE DRUG DOSE; NEUROTOXICITY; NONHUMAN; SINGLE DRUG DOSE; URINALYSIS; ANIMAL; ANIMAL DISEASE; BLOOD; SERODIAGNOSIS;

ANIMALIA; EQUIDAE; MURINAE;

ANIMALS; ENDOTOXINS; FEMALE; HORSES; LIPOPOLYSACCHARIDES; MALE; NEUTRALIZATION TESTS; POLYMYXIN B;

EID: 33646826180     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.4.642     Document Type: Article

References (51)

1. Hellman J, Warren HS. Antiendotoxin strategies. Infect Dis Clin North Am 1999;13:371-386.
2. Barton MH, Morris DD, Norton N, et al. Hemostatic and fibrinolytic indices in neonatal foals with presumed septicemia. J Vet Intern Med 1998;12:26-35.
3. Barton MH, Collates C. Tumor necrosis factor and interleukin-6 activity and endotoxin concentration in peritoneal fluid and blood of horses with acute abdominal disease. J Vet Intern Med 1999;13:457-464.
4. Morris DD, Moore JN, Crewe N. Serum tumor necrosis factor activity in horses with colic attributable to gastrointestinal tract disease. Am J Vet Res 1991;52:1565-1569.
5. Kirikae T, Nakano M, Morrison DC. Antibiotic-induced endotoxin release from bacteria and its clinical significance. Microbiol Immunol 1997;41:285-294.
6. Shenep JL. Antibiotic-induced bacterial cell lysis: a therapeutic dilemma. Eur J Clin Microbiol 1986;5:11-12.
7. Takakuwa T, Endo S, Nakae H, et al. Blood cytokine and complement levels in patients with sepsis. Res Commun Chem Pathol Pharmacol 1994;84:291-300.
8. Yoo HS, Maheswaran SK, Lin G, et al. Induction of inflammatory cytokines in bovine alveolar macrophages following stimulation with Pasteurella haemolytica lipopolysaccharide. Infect Immun 1995;63:381-388.
9. Appelmelk BJ, Cohen J, Silva A, et al. Further characterization of monoclonal antibodies to lipopolysaccharide of Salmonella Minnesota strain R595. Adv Exp Med Biol 1990;256:319-330.
10. Warren HS, Amato SF, Fitting C, et al. Assessment of ability of routine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med 1993;177:89-97.
11. Wheeler AP, Bernard GR. Applications of molecular biology and biotechnology: antibody therapy of sepsis. J Crit Care 1996;11:77-94.
12. Spier SJ, Lavoie JP, Cullor JS, et al. Protection against clinical endotoxemia in horses by using plasma containing antibody to an Rc mutant E. coli (J5). Circ Shock 1989;28:235-248.
13. Durando MM, MacKay RJ, Linda S, et al. Effects of polymyxin B and Salmonella typhimurium antiserum on horses given endotoxin intravenously. Am J Vet Res 1994;55:921-927.
14. Aida Y, Kusumoto K, Nakatomi K, et al. An analogue of lipid A and LPS from Rhodobacter sphaeroides inhibits neutrophil responses to LPS by blocking receptor recognition of LPS and by depleting LPS-binding protein in plasma. J Leukoc Biol 1995;58:675-682.
15. Chase JJ, Kubey W, Dulek MH, et al. Effect of monophosphoryl lipid A on host resistance to bacterial infection. Infect Immun 1986;53:711-712.
16. Danner RL, Van Dervort AL, Doerfler ME, et al. Antiendotoxin activity of lipid A analogues: requirements of the chemical structure. Pharm Res 1990;7:260-263.
17. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu Rev Biochem 1977;46:723-763.
18. Raisbeck MF, Garner HE, Osweiler GD. Effects of Polymyxin B on selected features of equine carbohydrate overload. Vet Hum Toxicol 1989;31:422-426.
19. Bader J, Teuber M. Action of polymyxin B on bacterial membranes. I. Binding to the O-antigenic lipopolysaccharide of Salmonella typhimurium. Z Naturforsch [C] 1973;28:422-430.
20. Morrison DC, Jacobs DM. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 1976;13:813-818.
21. Rustici A, Velucchi M, Faggioni R, et al. Molecular mapping and detoxification of the lipid A binding site by synthetic peptides. Science 1993;259:361-365.
22. Ried C, Wahl C, Miethke T, et al. High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant Limulus anti-lipopolysaccharide factor. J Biol Chem 1996;271:28120-28127.
23. Tsuzuki H, Tani T, Ueyama H, et al. Lipopolysaccharide: neutralization by polymyxin B shuts down the signaling pathway of nuclear factor kappaB in peripheral blood mononuclear cells, even during activation. J Surg Res 2001;100:127-134.
24. Sanders WE Jr, Sanders CC. Toxicity of antibacterial agents: mechanism of action on mammalian cells. Annu Rev Pharmacol Toxicol 1979;19:53-83.
25. Barton MH, Parviainen A, Norton N. Polymyxin B protects horses against induced endotoxaemia in vivo. Equine Vet J 2004;36:397-401.
26. MacKay RJ, Clark CK, Logdberg L, et al. Effect of a conjugate of polymyxin B-dextran 70 in horses with experimentally induced endotoxemia. Am J Vet Res 1999;60:68-75.
27. Parviainen AK, Barton MH, Norton NN. Evaluation of polymyxin B in an ex vivo model of endotoxemia in horses. Am J Vet Res 2001;62:72-76.
28. Green SJ. Oxidative metabolism of murine macrophages. In: Editorial Board, eds. Current protocols in immunology. New York: Greene Publications Associates & Wiley-Interscience, 1998;14.5.6-14.5.11.
29. Gibaldi M, Perrier D. Noncompartmental analysis based on statistical moment theory. In: Gibaldi M, Perrier D, eds. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc, 1982;409-417.
30. Meyer DS, Harvey JW. Assessment of renal function, urinalysis and water balance. In: Meyer DS, Harvey JW, eds. Veterinary laboratory medicine. Philadelphia: WB Saunders Co, 1998;221-235.
31. King JN, Gerring EL. Detection of endotoxin in cases of equine colic. Vet Rec 1988;123:269-271.
32. Mollett TA, Elmore RG, Blanchard TL, et al. Effects of intrauterine infusion of Escherichia coli endotoxin in anestrous and steroid treated pony mares. Theriogenology 1985;23:597-606.
33. Jack RS, Fan X, Bernheiden M, et al. Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. Nature 1997;389:742-745.
34. Flynn PM, Shenep JL, Stokes DC, et al. Polymyxin B moderates acidosis and hypotension in established, experimental gram-negative septicemia. J Infect Dis 1987;156:706-712.
35. Kunin CM, Bugg A. Recovery of tissue bound polymyxin B and colistimethate. Proc Soc Exp Biol Med 1971;137:786-790.
36. Danner RL, Joiner KA, Rubin M, et al. Purification, toxicity, and Antiendotoxin activity of polymyxin B nonapeptide. Antimicrob Agents Chemother 1989;33:1428-1434.
37. Ziv G, Nouws JF, van Ginneken CA. The pharmacokinetics and tissue levels of polymyxin B, colistin and gentamicin in calves. J Vet Pharmacol Ther 1982;5:45-58.
38. Kunin CM, Bugg A. Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J Infect Dis 1971;124:394-400.
39. Kunin CM. Nephrotoxicity of antibiotics. JAMA 1967;202:204-208.
40. Komiya S, Tachibana M. Target sites of polymyxin B ototoxicity. Eur Arch Otorhinolaryngol 1990;247:129-130.
41. de Silva AJ, Lee C. Neuromuscular and cardiovascular depression produced by prolonged exposure to polymyxin B. Can Anaesth Soc J 1978;25:303-306.
42. Bruckner J, Thomas KC Jr, Bikhazi GB, et al. Neuromuscular drug interactions of clinical importance. Anesth Analg 1980;59:678-682.
43. Drabick JJ, Bhattacharjee AK, Hoover DL, et al. Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent. Antimicrob Agents Chemother 1998;42:583-588.
44. Larter WE, Corrigan JJ Jr, Fulginiti VA. In vivo effect of polymyxin B on pertussis vaccine. Am J Dis Child 1984;138:281-283.
45. Bosso JA, Liptak CA, Seilheimer DK, et al. Toxicity of colistin in cystic fibrosis patients. DICP 1991;25:1168-1170.
46. Hermsen ED, Sullivan CJ, Rotschafer JC. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am 2003;17:545-562.
47. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999;33:960-967.
48. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 2001;7:434-440.
49. Nakamura T, Ebihara I, Shoji H, et al. Treatment with polymyxin B-immobilized fiber reduces platelet activation in septic shock patients: decrease in plasma levels of soluble P-selectin, platelet factor 4 and beta-thromboglobulin. Inflamm Res 1999;48:171-175.
50. Tani T, Hanasawa K, Kodama M, et al. Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor-1 activities in septic patients. World J Surg 2001;25:660-668.
51. Veenman JN, Dujardint CL, Hoek A, et al. High volume continuous venovenous haemofiltration (HV-CVVH) in an equine endotoxaemic shock model. Equine Vet J 2002;34:516-522.